Cargando…
Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
This open-label, single-arm, multicenter, 13-week, prospective study explored the efficacy, safety, and tolerability of paliperidone palmitate (150 milligram equivalents [mg eq] [day 1], 100 mg eq [day 8], both deltoid injections; 75–150 mg eq, deltoid/gluteal injection) in Chinese patients with acu...
Autores principales: | Si, Tianmei, Zhang, Kerang, Tang, Jisheng, Fang, Maosheng, Li, Keqing, Zhuo, Jianmin, Feng, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484695/ https://www.ncbi.nlm.nih.gov/pubmed/26150719 http://dx.doi.org/10.2147/NDT.S81760 |
Ejemplares similares
-
An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si, TianMei, et al.
Publicado: (2015) -
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si, Tianmei, et al.
Publicado: (2019) -
Dose Adjustment Model of Paliperidone in Patients With Acute Schizophrenia: A post hoc Analysis of an Open-Label, Single-Arm Multicenter Study
por: Si, Tianmei, et al.
Publicado: (2021) -
Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence
por: Si, Tianmei, et al.
Publicado: (2018) -
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao, Jingping, et al.
Publicado: (2017)